drugset
drugset / Trial / NCT05359692

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT05359692 ↗

Phase 2 Withdrawn Incyte Corporation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety, tolerability, efficacy, PK and pharmacodynamics of INCAGN01876 when given in combination with retifanlimab. The study will consist of 2 parts: a safety lead-in part (Part 1) followed by a dose expansion part (Part 2).

Timeline

Start
2023-03-01
Primary completion
2024-04-20
Completion
2025-01-11

Outcome

Outcome not reported

Stopped (Business): “Business decision; no safety concerns”

Drugs

EvaluationDrugModalityDoseRoute
Subject RAGIFILIMAB Monoclonal antibody — Intravenous
Subject Retifanlimab Monoclonal antibody — Intravenous

Indications

head and neck squamous cell carcinoma